The Impact of Omitting 5-FU Bolus From mFOLFOX6 Chemotherapy Regimen on Hematological Adverse Events Among Patients With Metastatic Colorectal Cancer

BACKGROUND: Metastatic colorectal cancer (mCRC) is often treated with a mFOLFOX6 regimen. The 5-fluorouracil (5-FU) bolus is often omitted from the regimen to reduce the risk of hematological adverse events (AEs) in patients with poor performance status. We aimed to investigate the incidence of hema...

Descripción completa

Detalles Bibliográficos
Autores principales: Areepium, Nutthada, Sapapsap, Bannawich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588498/
https://www.ncbi.nlm.nih.gov/pubmed/37869236
http://dx.doi.org/10.14740/wjon1690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588498/
https://www.ncbi.nlm.nih.gov/pubmed/37869236
http://dx.doi.org/10.14740/wjon1690

Ejemplares similares